<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clarithromycin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clarithromycin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clarithromycin: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12226" href="/d/html/12226.html" rel="external">see "Clarithromycin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13165" href="/d/html/13165.html" rel="external">see "Clarithromycin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866365"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Clarithromycin XL;</li>
<li>APO-Clarithromycin;</li>
<li>APO-Clarithromycin XL;</li>
<li>Biaxin;</li>
<li>Biaxin XL [DSC];</li>
<li>DOM-Clarithromycin;</li>
<li>GEN-Clarithromycin;</li>
<li>M-Clarithromycin;</li>
<li>PMS-Clarithromycin;</li>
<li>RIVA-Clarithromycin [DSC];</li>
<li>SANDOZ Clarithromycin;</li>
<li>TARO-Clarithromycin;</li>
<li>TEVA-Clarithromycin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F152420"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Macrolide</li></ul></div>
<div class="block doa drugH1Div" id="F152377"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> IR and ER formulations are available; 500 mg every 12 hours of immediate release is equivalent to 1 g of extended release (two 500 mg ER tablets) once daily.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Bartonella</i> spp. infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Bacillary angiomatosis, cat scratch disease, peliosis hepatitis, bacteremia, or osteomyelitis (alternative agent): <b>Note: </b>Not to be used for endocarditis or CNS infections.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Suppressive therapy:</i> Note:</b> For patients who experience a relapse after receiving a ≥3-month course of primary treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Immediate release: 500 mg twice daily. Continue until patient has received ≥3 months of therapy and CD4 count is &gt;200 cells/mm<sup>3</sup> for ≥6 months; some experts discontinue only if <i>Bartonella</i> titers have also decreased 4-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Cat scratch disease, lymphadenitis (alternative agent): <b>Oral:</b> Immediate release: 500 mg twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2e275dc-1491-4cbb-a975-cee9ed0644d5">Bronchiolitis obliterans, including diffuse panbronchiolitis and symptomatic cryptogenic bronchiolitis obliterans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchiolitis obliterans, including diffuse panbronchiolitis and symptomatic cryptogenic bronchiolitis obliterans (off-label use): Oral:</b> Immediate release: 250 to 500 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12854636','lexi-content-ref-King.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12854636','lexi-content-ref-King.2020'])">Ref</a></span>). After a 3- to 6-month trial, long-term therapy may be continued based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-King.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-King.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b>
<b>Note: </b>Avoid use in patients with risk factors for <i>Pseudomonas</i> infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg every 12 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467303','lexi-content-ref-GOLD.1','lexi-content-ref-11529259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467303','lexi-content-ref-GOLD.1','lexi-content-ref-11529259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e507892b-ac15-48ce-b58f-f7c4d1eaf4c8">Endocarditis prophylaxis, dental or invasive respiratory tract procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis prophylaxis, dental or invasive respiratory tract procedure (alternative agent for patients with penicillin allergy) (off-label use):</b>
<b>Oral:</b> Immediate release: 500 mg administered 30 to 60 minutes prior to procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. <b>Note:</b> Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17446442','lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17446442','lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori </i>eradication</b>
<b>: Note:</b> Avoid clarithromycin-based therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates ≥15% [which is assumed in the United States] or eradication rates with clarithromycin triple therapy ≤85%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-Crowe.1','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-Crowe.1','lexi-content-ref-27102658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for 7 to 14 days as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-Crowe.1','lexi-content-ref-27102658','lexi-content-ref-30978536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-Crowe.1','lexi-content-ref-27102658','lexi-content-ref-30978536'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycobacterium avium</i> complex infection:</p>
<p style="text-indent:-2em;margin-left:6em;">Disseminated disease in patients with HIV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment:</i>
<b>Oral:</b> Immediate release: 500 mg twice daily as part of an appropriate combination regimen for a minimum of 12 months; subsequently may discontinue once there are no signs/symptoms of <i>Mycobacterium avium</i> complex disease and the CD4 count has exceeded 100 cells/mm<sup>3</sup> for &gt;6 months in response to antiretroviral therapy (ART) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Primary prophylaxis: </i>
<b>Note: </b>Not routinely recommended; reserve for patients with CD4 count &lt;50 cells/mm<sup>3 </sup>who are <b>not</b> initiated on fully suppressive ART.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> Immediate release: 500 mg twice daily; may discontinue prophylaxis when patient is initiated on effective ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-30043070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-30043070'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary disease, nonsevere noncavitary nodular/bronchiectatic disease in patients without cystic fibrosis (alternative agent) (off-label use): <b>Oral:</b> Immediate release: 500 mg twice daily 3 times weekly as part of an appropriate combination regimen; continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary disease, severe nodular/bronchiectatic disease, cavitary disease, or disease in patients with cystic fibrosis (alternative agent) (off-label use): <b>Oral:</b> Immediate release: 500 mg twice daily as part of an appropriate combination regimen. Continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Rapidly growing nontuberculous mycobacterial (eg, <i>M. abscessus</i> infection) (off-label use): <b>Note:</b> Perform susceptibility testing before and after ≥14 days of clarithromycin incubation to evaluate for the presence of an inducible <i>erm</i> gene, which can result in decreased macrolide susceptibility even with a “susceptible” MIC result and may preclude use of clarithromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary, skin, soft tissue, or bone infection: <b>Oral:</b> Immediate release: 500 mg twice daily as part of an appropriate combination regimen and continued for ≥6 to 12 months for pulmonary and bone infections and ≥4 months for skin/soft tissue infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.1'])">Ref</a></span>). <b>Note:</b> Patients should be under the care of a clinician with expertise in managing mycobacterial infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c43d016-c199-4561-bd12-4713812696da">Pertussis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: <b>Note: </b>Treatment should be initiated within 21 days of cough onset. After this interval, some experts reserve treatment for pregnant women, patients &gt;65 years of age, and those with asthma, chronic obstructive pulmonary disease, or immunocompromising conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cornia.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cornia.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Postexposure prophylaxis: <b>Note:</b> Postexposure prophylaxis should be administered, regardless of vaccination history, to close contacts of persons with pertussis during the first 21 days of cough.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Inpatient: <b>Oral:</b> Immediate release: 500 mg twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Outpatient: <b>Oral:</b> 500 mg (immediate release) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>) or 1 g (two 500 mg ER tablets) once daily.<b> Note:</b> Use as part of an appropriate combination regimen; if local pneumococcal macrolide resistance is &lt;25%, monotherapy is an alternative approach for outpatients without comorbidities or risk factors for antibiotic-resistant pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: Minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee8efb2f-e456-4469-b78b-759eb66e5e69">Q fever, acute symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q fever (<i>Coxiella burnetii</i>), acute symptomatic (alternative agent) (off-label use):</b>
<b>Note:</b> Treatment is most effective if given within the first 3 days of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757','lexi-content-ref-11709360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757','lexi-content-ref-11709360'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>). Given increased resistance in <i>S. pneumoniae</i>, macrolides, including clarithromycin, are not recommended for empiric treatment of acute bacterial rhinosinusitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: 500 mg twice daily (manufacturer’s labeling) for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for patients with severe penicillin allergy):</b>
<b>Oral:</b> Immediate release: 250 mg twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991428"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<table border="1" frame="border" rules="all">
<caption>
<b>Clarithromycin Dosage Adjustments in Altered Kidney Function<sup>a</sup>: Oral</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><tfoot valign="middle">
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>a </sup>Davey 1991; Fraschini 1993; Hardy 1992; manufacturer’s labeling</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>b </sup>CrCl determined using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>c</sup> IR = immediate release</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>d</sup> ER = extended release</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>e </sup>IR product would be equally effective (expert opinion).</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>f </sup>No pharmacokinetic data in hemodialysis/peritoneal dialysis patients; recommendations are based on expert opinion only.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>g </sup>Although unlikely to be significantly dialyzed (manufacturer’s labeling), because no data on degree of dialyzability are available, consider administering after dialysis when scheduled dose falls on dialysis days.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">If the usual recommended dose is IR<sup>c</sup> 250 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">If the usual recommended dose is IR 500 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">If the usual recommended dose is ER<sup>d</sup> 1 g once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg twice daily or 500 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">ER: 500 mg once daily<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Intermittent hemodialysis, thrice weekly<sup>f,g</sup></p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg twice daily or 500 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">ER: 500 mg once daily<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis<sup>f</sup></p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">IR: 250 mg twice daily or 500 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">ER: 500 mg once daily<sup>e</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Unlikely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Follow dosing recommendations for patients with CrCl &lt;30 mL/minute. <b>Note:</b> In general, use of IV antimicrobial therapy may be preferred in patients receiving CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Unlikely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Follow dosing recommendations for patients with CrCl &lt;30 mL/minute.<b>
<b>Note:</b></b> In general, use of IV antimicrobial therapy may be preferred in patients receiving PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988703"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary if renal function is normal; however, in patients with hepatic impairment and concomitant severe renal impairment, a dosage reduction or prolonged dosing intervals may be appropriate.</p></div>
<div class="block doe drugH1Div" id="F152378"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F152399"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13165" href="/d/html/13165.html" rel="external">see "Clarithromycin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf06c579-3783-44e8-9dd5-e091ef8a705e">Bartonellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bartonellosis: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary treatment (alternative agent)</i>: Adolescents, HIV-infected: Immediate release: Oral: 500 mg twice daily for ≥3 months. After completion of therapy, closely monitor for relapse; if relapse occurs, an additional course of treatment followed by long-term suppression is recommended. <b>Note:</b> Should not be used for endocarditis or CNS infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative agent for use in patients with penicillin or ampicillin allergy. Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 15 mg/kg as a single dose administered 30 to 60 minutes prior to dental procedure; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i> eradication</b>
<b>:</b> Limited data available: <b>Note:</b> Use as part of an appropriate combination regimen; usual duration of therapy is 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541262'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Children and Adolescents: Immediate release: Oral: 7.5 to 10 mg/kg/dose twice daily; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21701406','lexi-content-ref-28653787','lexi-content-ref-24117692','lexi-content-ref-21558964','lexi-content-ref-25171023','lexi-content-ref-19330931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21701406','lexi-content-ref-28653787','lexi-content-ref-24117692','lexi-content-ref-21558964','lexi-content-ref-25171023','lexi-content-ref-19330931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541262'])">Ref</a></span>): Children and Adolescents: Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;25 kg: Oral: 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">25 to &lt;35 kg: Oral: 500 mg in the morning and 250 mg in the evening.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: Oral: 500 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e096d904-52ea-4eb0-a6d7-1e796cc45b21">Lyme disease, erythema migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia </i>spp. infection), erythema migrans (alternative agent):</b> Limited data available: <b>Note: </b>Current guidelines recommend macrolides (azithromycin) only when first-line agents cannot be used due to lower efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg twice daily for 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22760494','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22760494','lexi-content-ref-17029130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97ac6a05-38e1-4b48-b518-54076eba0185">Mycobacterial infection, nontuberculous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial infection, nontuberculous: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycobacterium avium complex infection in patients that are HIV-exposed/-infected</i>: (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.4'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Limited data available in Infants and Children &lt;20 months:</p>
<p style="text-indent:-2em;margin-left:8em;">Primary prophylaxis (patients who meet age-specific CD4 count thresholds): Immediate release: Oral: 7.5 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment: Immediate release: Oral: 7.5 to 15 mg/kg/dose every 12 hours as part of an appropriate combination regimen for ≥12 months; maximum dose: 500 mg/dose; follow with chronic maintenance therapy (secondary prophylaxis).</p>
<p style="text-indent:-2em;margin-left:8em;">Chronic maintenance therapy (secondary prophylaxis): Immediate release: Oral: 7.5 mg/kg/dose every 12 hours as part of an appropriate combination regimen; maximum dose: 500 mg/dose. May be discontinued once there are no signs/symptoms of <i>M. avium </i>complex disease, and the CD4 count has exceeded age-specific thresholds for ≥6 months in response to stable antiretroviral therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary infection in patients with or without cystic fibrosis (eg, M. avium complex, Mycobacterium abscessus):</i> Limited data available: Infants, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours for ≥12 months after culture conversion; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (AOM) (alternative agent for patients who cannot tolerate beta-lactam antibiotics): Note:</b> Not recommended for routine empiric use due to limited efficacy against <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). For patients with severe or recurrent AOM, tympanic membrane perforation, or who are &lt;2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, nonrecurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89f41be0-1b3d-4017-bca9-ef5a9b43a4ec">Peritonitis, prophylaxis for patients requiring invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), prophylaxis for patients requiring invasive dental procedures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Immediate release: Oral: 15 mg/kg as a single dose 30 to 60 minutes prior to dental procedure; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f573e1c-a236-4e93-a9e3-ccd522d76fbf">Pertussis, treatment or postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis, treatment or postexposure prophylaxis:</b> Infants, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours for 7 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a390759b-e4ea-4792-b0c2-fd3637bb4f8e">Pneumonia, community-acquired; mild infection or step-down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (presumed or proven atypical pneumonia); mild infection or step-down therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours for 10 days; shorter courses may be appropriate for mild disease; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for severe penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: Immediate release: Oral: 7.5 mg/kg/dose every 12 hours for 10 days; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51089928"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on a dose of 7.5 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Immediate release: 4 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Immediate release: 4 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer after hemodialysis session is completed: Immediate release: 4 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Immediate release: 4 mg/kg/dose once daily.</p></div>
<div class="block dohp drugH1Div" id="F51089929"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥6 months, Children, and Adolescents: No dosage adjustment necessary if renal function is normal; however, in patients with hepatic impairment and concomitant severe renal impairment, a dosage reduction or prolonged dosing intervals may be appropriate.</p></div>
<div class="block adr drugH1Div" id="F152338"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (2%), insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (children 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (adults 3% to 7%), vomiting (children 6%), diarrhea (3% to 6%), nausea (adults 3%), abdominal pain (2% to 3%), dyspepsia (adults 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Prolonged prothrombin time (adults 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (including oral)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distension, abnormal albumin-globulin ratio, acne vulgaris, acute generalized exanthematous pustulosis, ageusia, agranulocytosis, altered sense of smell, anaphylaxis, angioedema, anorexia, anosmia, anxiety, asthma, atrial fibrillation, behavioral changes, bullous dermatitis, cellulitis, chest pain, chills, cholestasis, cholestatic hepatitis, <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea, <i>Clostridioides</i>
<i>difficile </i>(colitis), confusion, constipation, dark urine (abnormal urine color associated with liver injury), decreased appetite, decreased white blood cell count, dental discoloration (reversible with dental cleaning), depersonalization, depression, disorientation, dizziness, DRESS syndrome, drowsiness, dyskinesia, eosinophilia, epistaxis, eructation, esophagitis, extrasystoles, fatigue, fever, flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, glossitis, hallucination, hearing loss (reversible), hemorrhage, hepatic failure, hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperhidrosis, hypersensitivity reaction, hypoglycemia, IgA vasculitis, increased gamma-glutamyl transferase, increased INR, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, infection, interstitial nephritis, jaundice, leukopenia, loss of consciousness, maculopapular rash, malaise, manic behavior, muscle spasm, myalgia, myopathy, neck stiffness, nervousness, neutropenia, nightmares, palpitations, pancreatitis, parasomnias, paresthesia, prolonged QT interval on ECG, pruritus, pseudomembranous colitis, psychosis, pulmonary embolism, rectal pain, renal failure, rhabdomyolysis, seizure, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, tinnitus, tongue discoloration, torsades de pointes, toxic epidermal necrolysis, tremor, urticaria, vaginal infection, ventricular arrhythmia, ventricular tachycardia, vertigo, weakness, xerostomia</p></div>
<div class="block coi drugH1Div" id="F152352"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to clarithromycin, erythromycin, any of the macrolide antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin; concomitant use with cisapride, ergot alkaloids (eg, ergotamine, dihydroergotamine), HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (eg, lovastatin, simvastatin), lomitapide, or pimozide; concomitant use with colchicine in patients with renal or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Severe hepatic failure in combination with renal impairment; history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes; hypokalemia; hypomagnesemia; concomitant use with astemizole, colchicine (regardless of hepatic/renal impairment), domperidone, midazolam (oral), ranolazine (not available in Canada), saquinavir, terfenadine, or ticagrelor.</p></div>
<div class="block war drugH1Div" id="F152335"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Use has been associated with QT prolongation and infrequent cases of arrhythmias, including torsades de pointes (may be fatal); avoid use in patients with known prolongation of the QT interval, ventricular cardiac arrhythmia (including torsades de pointes), uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and patients receiving Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Elevated liver function tests and hepatitis (hepatocellular and/or cholestatic with or without jaundice) have been reported; usually reversible after discontinuation of clarithromycin. May lead to hepatic failure or death (rarely), especially in the presence of preexisting diseases and/or concomitant use of medications. Discontinue immediately if symptoms of hepatitis (eg, anorexia, jaundice, abdominal tenderness, pruritus, dark urine) occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe acute reactions have been reported, including anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schönlein purpura (IgA vasculitis), and acute generalized exanthematous pustulosis; discontinue therapy and initiate treatment immediately for severe acute hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CAD: Use with caution in patients with CAD. A clinical trial in patients with CAD demonstrated an increase in risk of all-cause mortality ≥1 year after the end of treatment in patients randomized to receive clarithromycin. Other epidemiologic studies evaluating this risk have variable results.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms and new onset of symptoms has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in severe renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; elderly patients may be at increased risk of torsades de pointes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with HIV: Decreased survival has been observed in patients with HIV with <i>Mycobacterium avium</i> complex (MAC) receiving clarithromycin doses above the maximum recommended dose; maximum recommended dosing should not be exceeded in this population. Development of resistance to clarithromycin has been observed when used as prophylaxis and treatment of MAC infection (Biaxin Canadian product labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended release formulation: The presence of extended release tablets in the stool has been reported, particularly in patients with anatomic (eg, ileostomy, colostomy) or functional GI disorders with decreased transit times. Consider alternative dosage forms (eg, suspension) or an alternative antimicrobial for patients with tablet residue in the stool and no signs of clinical improvement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (≤7 days) has been associated with a higher incidence of treatment failure. Current guidelines recommend 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> in pediatric and adult patients (Chey 2007; NASPHGAN [Koletzko 2011]).</p></div>
<div class="block foc drugH1Div" id="F152345"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F152331"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F152354"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Clarithromycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $1.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $2.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Clarithromycin ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $8.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Clarithromycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $4.52 - $6.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4.52 - $6.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866366"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biaxin: 125 mg/5 mL (55 mL, 105 mL); 250 mg/5 mL (105 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (55 mL, 105 mL, 150 mL); 250 mg/5 mL (105 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biaxin: 250 mg, 500 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biaxin XL: 500 mg [DSC] [contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block adm drugH1Div" id="F152349"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablets and granules for suspension: Administer with or without meals. Administer every 12 hours rather than twice daily to avoid peak and trough variation. Shake suspension well before each use.</p>
<p style="text-indent:-2em;margin-left:2em;">ER tablets: Administer with food. Do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation (tablet or oral solution).</p></div>
<div class="block admp drugH1Div" id="F52612431"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablets and oral suspension: May be administered with or without meals. Shake suspension well before each use.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release tablets: Administer with food. Do not break, crush, or chew.</p></div>
<div class="block use drugH1Div" id="F152348"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation: </b>Treatment of acute bacterial exacerbation of chronic bronchitis in adults due to susceptible <i>Haemophilus influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>Moraxella catarrhalis</i>, or <i>Streptococcus pneumoniae</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i> eradication:</b> Eradication of <i>Helicobacter pylori</i> to reduce the risk of duodenal ulcer recurrence as a component of combination therapy (triple therapy) in adults with <i>H. pylori</i> infection and duodenal ulcer disease (active or 5-year history of duodenal ulcer).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Regimens that contain clarithromycin as the single antibacterial agent are more likely to be associated with the development of clarithromycin resistance. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin-resistant isolates (efficacy is reduced).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) infection:</b> Prophylaxis and treatment of disseminated mycobacterial infections due to <i>Mycobacterium avium</i> complex (MAC) in patients with advanced HIV infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media:</b> Treatment of acute otitis media in pediatric patients due to susceptible <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Treatment of community-acquired pneumonia due to susceptible <i>Mycoplasma pneumoniae</i>, <i>S. pneumoniae</i>, or <i>Chlamydophila pneumoniae </i>(adult and pediatric patients) and<i> H. influenzae, H. parainfluenzae, </i>or<i> M. catarrhalis </i>(adults)<i>.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b> Treatment of acute bacterial rhinosinusitis caused by susceptible strains of <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i>. <b>Note:</b> Given increased <i>S. pneumoniae</i> resistance, macrolides, including clarithromycin, are not recommended for empiric treatment of bacterial rhinosinusitis (AAO-HNS [Rosenfeld 2015]; IDSA [Chow 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin/skin structure infection:</b> Treatment of uncomplicated skin/skin structure infection due to susceptible <i>Staphylococcus aureus</i> or <i>Streptococcus pyogenes.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A:</b> Treatment of pharyngitis/tonsillitis due to susceptible <i>S. pyogenes</i> (alternative agent for patients with severe penicillin allergy).</p></div>
<div class="block off-label drugH1Div" id="F26122358"><span class="drugH1">Use: Off-Label: Adult</span><p>Bartonella spp. infection; Bronchiolitis obliterans, including diffuse panbronchiolitis and symptomatic cryptogenic bronchiolitis obliterans; Endocarditis, prophylaxis; Mycobacterial (nontuberculous, rapidly growing) infection; Pertussis; Q fever (Coxiella burnetii), acute symptomatic</p></div>
<div class="block mst drugH1Div" id="F152427"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Clarithromycin may be confused with Claritin, clindamycin, erythromycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F152413"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (strong), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F152340"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib.  Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.  Management: Avoid concomitant use of ado-trastuzumab emtansine and strong CYP3A4 inhibitors when possible. Consider alternatives that do not inhibit CYP3A4 or consider administering after CYP3A4 inhibitor discontinuation. Monitor for toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and strong CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan dose to 6.25 mg and maximum dose to 12.5 mg in any 24-period when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Clarithromycin. Management: Avoid clarithromycin doses greater than 1,000 mg/day when used with an antihepaciviral combination product. Further dose reductions may be needed in patients with impaired renal function. Consider an alternative antimicrobial for any non-MAC infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Clarithromycin may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose reductions are required for indications other than major depressive disorder. Dose reductions vary based on formulation, initial starting dose, CYP2D6 genotype, and use of CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Decrease aripiprazole lauroxil dose to next lower strength if used with strong CYP3A4 inhibitors for over 14 days. No dose adjustment needed if using the lowest dose (441 mg). Max dose is 441 mg in CYP2D6 PMs or if also taking strong CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asciminib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Astemizole. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease serum concentrations of the active metabolite(s) of Clarithromycin. Atazanavir may increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Atazanavir. Management: Decrease clarithromycin dose 50% and do not exceed 1,000 mg per day. Decrease clarithromycin dose 75% in patients with CrCL less than 30 mL/min. Use alternative antimicrobial therapy if treating infections other than <i>Mycobacterium avium</i> complex.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended atogepant dose is 10 mg once daily with a concurrent strong CYP3A4 inhibitor. If used for treatment of chronic migraine, concurrent use of atogepant with strong CYP3A4 inhibitors should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Atogepant.  Management: For episodic migraine, the recommended atogepant dose is 10 mg or 30 mg once daily if given with OATP1B1/1B3 inhibitors. For chronic migraine, the recommended atogepant dose is 30 mg once daily with OATP1B1/1B3 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Clarithromycin may increase the serum concentration of Atorvastatin.  Management: Limit atorvastatin to a maximum dose of 20 mg/day when used with clarithromycin.  If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avacopan.  Management: Decrease the avacopan dose to 30 mg once daily during coadministration with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beclomethasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Beclomethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Betamethasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Specifically, bosentan may increase concentrations of 14-hydroxyclarithromycin. Bosentan may decrease the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Bosentan. Management: Consider alternative antimicrobial if possible. The clinical activity of clarithromycin may be altered, and increased bosentan toxicity may be expected.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose 50% with strong CYP3A4 inhibitors; reduce to 25% of usual if used with both a strong CYP3A4 inhibitor and a CYP2D6 inhibitor in patients not being treated for MDD, or strong CYP3A4 inhibitor used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Brincidofovir.  Management: Consider alternatives to OATP1B/1B3 inhibitors in patients treated with brincidofovir. If coadministration is required, administer OATP1B1/1B3 inhibitors at least 3 hours after brincidofovir and increase monitoring for brincidofovir adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine.  Management: Consider alternatives to the use of bromocriptine with strong CYP3A4 inhibitors. If combined, monitor closely for increased bromocriptine toxicities and consider bromocriptine dose reductions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased corticosteroid adverse effects during coadministration of inhaled budesonide and strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and a strong CYP3A4 inhibitor, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors. Dose adjustments of buspirone or a strong CYP3A4 inhibitor should be based on clinical assessment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible. If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: Clarithromycin may increase the serum concentration of Cabergoline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, decrease cabozantinib capsules (Cometriq) by 40 mg from previous dose or decrease cabozantinib tablets (Cabometyx) by 20 mg from previous dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Capivasertib.  Management: Avoid concomitant use of capivasertib with strong CYP3A4 inhibitors when possible. If combined, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Capmatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Clarithromycin. Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine effects/toxicities and for reduced clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Decrease cariprazine dose 50% (4.5 mg to 1.5 mg or 3 mg; 1.5 mg to 1.5 mg every other day) if starting a strong CYP3A4 inhibitor. If on a strong CYP3A4 inhibitor, start cariprazine at 1.5 mg day 1, 0 mg day 2, then 1.5 mg daily. May increase to 3 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ceritinib. Management: Avoid use of ceritinib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, decrease ceritinib dose by one-third (to the nearest 150 mg) and monitor patients for ceritinib toxicities including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ChlordiazePOXIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciclesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ciclesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cinacalcet: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cinacalcet. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Cisapride. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Citalopram. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease serum concentrations of the active metabolite(s) of Clarithromycin. Cobicistat may increase the serum concentration of Clarithromycin. Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir with estimated creatinine clearance 50 to 60 mL/min. Closely monitor for clarithromycin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of P-gp inhibitors, and hepatic/renal function. See interaction monograph for details<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cortisone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cortisone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Crizotinib. Management: Avoid concomitant use of crizotinib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, crizotinib dose adjustments are required, which vary according to indication. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Clarithromycin may increase the serum concentration of CycloSPORINE (Systemic).  Management: Monitor for increased serum concentrations/toxic effects of cyclosporine if combined with clarithromycin. Cyclosporine dose reductions and/or prolongation of the dosing interval will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin. Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Clarithromycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of Clarithromycin. Dabrafenib may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase serum concentrations of the active metabolite(s) of Dabrafenib. Clarithromycin may increase the serum concentration of Dabrafenib. Dabrafenib may increase the serum concentration of Clarithromycin. Management: If coadministration is unavoidable, monitor for decreased clarithromycin efficacy, increased dabrafenib adverse effects, and QTc interval prolongation and ventricular arrhythmias when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Darifenacin.  Management: Limit the darifenacin dose to no more than 7.5 mg daily if combined with strong CYP3A4 inhibitors. Monitor patients for increased darifenacin toxicities (eg, dry mouth, constipation, headache, CNS effects) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Darolutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dasatinib. Management: Avoid this combination if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. If taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued. Monitor for prolonged QT interval<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DexAMETHasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxazosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Doxazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Dronedarone. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Duvelisib.  Management: Reduce the dose of duvelisib to 15 mg twice a day when used together with a strong CYP3A4 inhibitor. Monitor closely for evidence of altered response to treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Clarithromycin may increase the serum concentration of Edoxaban.  Management: In patients treated for DVT/PE, reduce edoxaban dose to 30 mg daily when combined with clarithromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efonidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Efonidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elagolix. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elagolix, Estradiol, and Norethindrone. Specifically, concentrations of elagolix may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elagolix, Estradiol, and Norethindrone. Elagolix, Estradiol, and Norethindrone may decrease the serum concentration of CYP3A4 Inhibitors (Strong). Specifically, concentrations of strong CYP3A4 inhibitors that are also CYP3A4 substrates may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: Administer elexacaftor/tezacaftor/ivacaftor in the morning, twice a week, 3 to 4 days apart, with no evening doses of ivacaftor alone. Specific dosing varies by age and weight. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with strong CYP3A4 inhibitors. Use of strong CYP3A4 inhibitors is contraindicated in CYP2D6 IMs, PMs, or in CYP2D6 EMs who are also taking strong or moderate CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with OATP1B1/1B3 inhibitors and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: Clarithromycin may enhance the QTc-prolonging effect of Encorafenib. Encorafenib may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of Encorafenib. Encorafenib may decrease the serum concentration of Clarithromycin.  Management: Avoid this combination when possible. If combined, decrease encorafenib from 450 mg to 150 mg; or from 300 mg, 225 mg, or 150 mg to 75 mg. Additionally, monitor for decreased clarithromycin efficacy and for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Entrectinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erdafitinib.  Management: Avoid concomitant use of erdafitinib and strong CYP3A4 inhibitors when possible. If combined, monitor closely for erdafitinib adverse reactions and consider dose modifications accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of erlotinib-associated adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Erythromycin (Systemic). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fedratinib.  Management: Consider alternatives when possible. If used together, decrease fedratinib dose to 200 mg/day. After the inhibitor is stopped, increase fedratinib to 300 mg/day for the first 2 weeks and then to 400 mg/day as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Felodipine.  Management: Consider using lower felodipine doses when combined with strong CYP3A4 inhibitors. Monitor patients for increased felodipine effects and toxicities (eg, hypotension, edema) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a strong CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Limit fesoterodine doses to 4 mg daily in patients who are also receiving strong CYP3A4 inhibitors. This combination is not recommended in pediatric patients weighing 25 kg up to 35 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with strong CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flunitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Consider alternatives to this combination if possible. Coadministration of fluticasone propionate and strong CYP3A4 inhibitors is not recommended. If combined, monitor patients for systemic corticosteroid adverse effects (eg, adrenal suppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Galantamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Gilteritinib. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Gilteritinib.  Management: Consider alternatives to the use of gilteritinib with strong CYP3A4 inhibitors that prolong the QTc interval whenever possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Glasdegib.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor closely for evidence of QT interval prolongation and other adverse reactions to glasdegib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a strong CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrexafungerp.  Management: Decrease the ibrexafungerp dose to 150 mg every 12 hours for 2 doses in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib.  Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Idelalisib.  Management: Use alternative therapies that are not strong CYP3A4 inhibitors whenever possible. If unable to use alternative drugs, monitor patients more frequently for idelalisib toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased.  Management: Avoid administration of strong CYP3A4 inhibitors during and within 1 week prior to irinotecan administration, unless no therapeutic alternatives to these agents exist. If combined, monitor closely for increased irinotecan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Istradefylline.  Management: Limit the maximum istradefylline dose to 20 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased istradefylline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full drug interaction monograph content for age- and weight-specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.  Management: Avoid use of ixabepilone and strong CYP3A4 inhibitors when possible. If combined, reduce the ixabepilone dose to 20 mg/m<sup>2</sup>. The previous ixabepilone dose can be resumed 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: Avoid use of lapatinib and strong CYP3A4 inhibitors when possible. If combined, a reduced lapatinib dose of 500 mg daily should be considered. The previous lapatinib dose can be resumed 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inhibitors with larotrectinib. If this combination cannot be avoided, reduce the larotrectinib dose by 50%. Increase to previous dose after stopping the inhibitor after a period of 3 to 5 times the inhibitor's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets and strong inhibitors of CYP3A4.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Leuprolide and Norethindrone. Specifically, concentrations of norethindrone may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: The dose of levomilnacipran should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with strong CYP3A4 inhibitors. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily, or from 75 mg once daily to 50 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Lovastatin. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 10.5 mg once daily when used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and strong CYP3A4 inhibitors. If coadministration with a strong CYP3A4 inhibitor cannot be avoided, reduce the lurbinectedin dose by 50%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce maraviroc to 150mg twice/day in adult and pediatrics weighing 40kg or more. See full interaction monograph for dose adjustments in pediatrics weighing 10 to less than 40kg. Do not use if CrCl less than 30mL/min or in those weighing less than 10 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midazolam.  Management: Avoid use of nasal midazolam and strong CYP3A4 inhibitors whenever possible, and consider alternatives to use with other routes of midazolam (oral, IV, IM). If combined, consider lower midazolam doses and monitor for increased midazolam toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Midostaurin.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MiFEPRIStone.  Management: For treatment of hyperglycemia in Cushing's syndrome, start mifepristone at 300 mg/day, may titrate to a maximum of 900 mg/day. If starting a strong CYP3A4 inhibitor and taking &gt; 300 mg/day mifepristone, decrease the mifepristone dose by 300 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirvetuximab Soravtansine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirvetuximab Soravtansine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Momelotinib: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Momelotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mometasone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mometasone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Nevirapine may decrease the serum concentration of Clarithromycin. Management: Consider alternatives to clarithromycin, such as azithromycin, for the treatment of <i>Mycobacterium avium-intracellulare complex</i> in patients taking nevirapine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NIFEdipine.  Management: Consider alternatives to this combination when possible. If combined, initiate nifedipine at the lowest dose available and monitor patients closely for increased nifedipine effects and toxicities (eg, hypotension, edema).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Nilotinib. Management: Avoid concomitant use of nilotinib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, nilotinib dose reductions are required. Monitor patients for nilotinib toxicities including QTc prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 100 mg twice daily and the dose of olaparib capsules should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 50 mg daily and monitor closely for adverse reactions. Discontinue coadministration if adverse reactions occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Osilodrostat.  Management: Reduce osilodrostat dose by 50% during coadministration with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyBUTYnin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyBUTYnin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib.  Management: Avoid concurrent use of strong CYP3A4 inhibitors with palbociclib when possible. If the use of a strong CYP3A4 inhibitor cannot be avoided, decrease the palbociclib dose to 75 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor. Monitor patient response to therapy closely for evidence of more severe adverse effects related to panobinostat therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. Specifically, serum concentrations of the active moiety valdecoxib may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Clarithromycin may enhance the QTc-prolonging effect of PAZOPanib. Clarithromycin may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the strong inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin.  Management: Decrease the pimavanserin dose to 10 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Piperaquine.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use when possible. If combined, reduce the pirtobrutinib dose by 50 mg. If current dose is 50 mg, interrupt pirtobrutinib treatment during strong CYP3A4 inhibitor use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Avoid concomitant use if possible. If combined, reduce ponatinib dose as follows: If taking 45 mg, reduce to 30 mg; if taking 30 mg, reduce to 15 mg; if taking 15 mg, reduce to 10 mg. If taking 10 mg, avoid concomitant use with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Pralsetinib.  Management: Avoid concomitant use if possible. If combined, reduce the pralsetinib dose. If taking 400 mg or 300 mg once daily, reduce to 200 mg once daily. If taking 200 mg once daily, reduce to 100 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: Clarithromycin may increase the serum concentration of Pravastatin.  Management: Limit pravastatin to a maximum of 40 mg/day when used in combination with clarithromycin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Propofol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease serum concentrations of the active metabolite(s) of Clarithromycin. Protease Inhibitors may increase the serum concentration of Clarithromycin. Management: Do not exceed clarithromycin doses greater than 1,000 mg/day in patients taking protease inhibitors. If CrCL is 30 to 60 mL/min, reduced clarithromycin dose 50%. If CrCL is less than 30 mL/min, reduced clarithromycin dose 75%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Clarithromycin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Clarithromycin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine. Management: Reduce the quetiapine dose to one-sixth of the regular dose when initiating these strong CYP3A4 inhibitors. In patients already receiving these strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and titrate cautiously as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Quizartinib. Management: If combination is necessary, reduce quizartinib dose as follows: from 53 mg daily to 26.5 mg daily; from 35.4 mg daily to 17.7 mg daily; from 26.5 mg daily to 17.7 mg daily. If taking 17.7 mg daily avoid quizartinib while on the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: The use of retapamulin with strong CYP3A4 inhibitors is not recommended in patients less than 2 years old. No action is required in other populations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase serum concentrations of the active metabolite(s) of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ribociclib. Management: Avoid concomitant use of ribociclib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, decrease the ribociclib dose to 400 mg daily. Monitor for ribociclib toxicities including QTc prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Rifabutin may decrease the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Rifabutin. Management: Consider alternatives to this combination when possible. If combined, consider use of lower rifabutin doses and monitor patients for increased rifabutin toxicities. Additionally, monitor for reduced clarithromycin efficacy when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Macrolide Antibiotics may increase the serum concentration of Rilpivirine.  Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ripretinib. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ripretinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: May enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of RisperiDONE. Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Clarithromycin may increase the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib (Systemic).  Management: This combination should be avoided under some circumstances; dose adjustments may be required in some circumstances and depend on the indication for ruxolitinib. See monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of Saquinavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Limit the saxagliptin dose to 2.5 mg daily when combined with strong CYP3A4 inhibitors. When using the saxagliptin combination products saxagliptin/dapagliflozin or saxagliptin/dapagliflozin/metformin, avoid use with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose.  For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Sertindole. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sibutramine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Sibutramine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sibutramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: Use of sildenafil for pulmonary arterial hypertension (PAH) should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, consider using a lower starting dose of 25 mg and monitor patients for sildenafil toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with strong CYP3A4 inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Concomitant use of sirolimus and voriconazole or posaconazole is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Solifenacin.  Management: Limit adult solifenacin doses to 5 mg daily and limit doses in pediatric patients to the recommended weight-based starting dose (and do not increase the dose) when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Clarithromycin may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of SUNItinib. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, decrease sunitinib dose to a minimum of 37.5 mg daily when treating GIST or RCC. Decrease sunitinib dose to a minimum of 25 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tacrolimus (Systemic).  Management: Reduce tacrolimus dose to one-third of the original dose if starting posaconazole or voriconazole. Coadministration with nelfinavir is not generally recommended. Tacrolimus dose reductions or prolongation of dosing interval will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Avoid this combination in patients taking tadalafil for pulmonary arterial hypertension. In patients taking tadalafil for ED or BPH, max tadalafil dose is 2.5 mg if taking daily or 10 mg no more frequently than every 72 hours if used as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Clarithromycin may increase the serum concentration of Talazoparib.  Management: In breast cancer, if concurrent use cannot be avoided, reduce talazoparib dose to 0.75 mg once daily. In prostate cancer, monitor patients for increased adverse events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors. If coadministration is unavoidable, decrease temsirolimus dose to 12.5 mg per week. Resume previous temsirolimus dose 1 week after discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Terfenadine. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor should be administered in the morning, twice a week, approximately 3 to 4 days apart. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Clarithromycin may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Thiotepa.  Management: Avoid coadministration of thiotepa and strong CYP3A4 inhibitors. If concomitant use cannot be avoided, monitor for thiotepa adverse effects and decreased efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: Clarithromycin may increase the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Clarithromycin.  Management: Limit adult clarithromycin doses to 1,000 mg/day if combined with tipranavir. Consider reducing the clarithromycin dose by 50% for patients with CrCl 30 to 60 mL/min, and for patients with CrCl &lt;30 mL/min consider reducing the clarithromycin dose by 75%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tisotumab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tisotumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Tofacitinib dose reductions are recommended when combined with strong CYP3A4 inhibitors. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of tolterodine is 2 mg per day (1 mg twice daily for immediate-release tablets or 2 mg daily for extended-release capsules) when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Toremifene. Management: Avoid concomitant use of toremifene and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined, monitor patients for toremifene toxicities including QTc prolongation and TdP.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraZODone.  Management: Consider the use of a lower trazodone dose and monitor for increased trazodone effects (eg, sedation, QTc prolongation) if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Systemic).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased corticosteroid adverse effects during coadministration of triamcinolone and strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triamcinolone (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Upadacitinib.  Management: Upadacitinib dose adjustments are needed when combined with strong CYP3A4 inhibitors. Specific adjustments vary based on upadacitinib indication. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vamorolone.  Management: Reduce the vamorolone dose to 4 mg/kg daily, with a maximum dose of 200 mg daily for patients weighing over 50 kg, when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 2.5 mg dose within a 24-hour period if combined with strong CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and strong CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: May enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Vemurafenib. Management: Avoid concomitant use of vemurafenib and strong CYP3A4 inhibitors that prolong the QTc interval whenever possible. If combined monitor patients for vemurafenib toxicities including QTc prolongation and TdP, and consider a vemurafenib dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: Coadministration is contraindicated during venetoclax initiation and ramp-up in CLL/SLL patients. Reduced venetoclax doses are required during ramp-up for patients with AML, and all maintenance therapy. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilanterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilanterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit the maximum vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine.  Management: Seek alternatives to this combination when possible. If combined, monitor closely for vincristine toxicities (eg, neurotoxicity, gastrointestinal toxicity, myelosuppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Clarithromycin may enhance the QTc-prolonging effect of Voriconazole. Voriconazole may increase the serum concentration of Clarithromycin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg once daily during coadministration with a strong CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.  Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: If coadministered with strong CYP3A4 inhibitors, initiate zopiclone at 3.75 mg in adults, with a maximum dose of 5 mg. Monitor for zopiclone toxicity (eg, drowsiness, confusion, lethargy, ataxia, respiratory depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuranolone.  Management: Reduce the zuranolone dose to 30 mg once daily when used concomitantly with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F152368"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Immediate release: Food delays rate, but not extent of absorption; Extended release: Food increases clarithromycin AUC by ~30% relative to fasting conditions. Management: Administer immediate release products without regard to meals. Administer extended release products with food.</p></div>
<div class="block pri drugH1Div" id="F152355"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clarithromycin crosses the placenta (Witt 2003).</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends that clarithromycin not be used in pregnant patients unless there are no alternative therapies. Clarithromycin is not recommended as a first-line agent for the treatment or prophylaxis of <i>Mycobacterium avium</i> complex in pregnant patients living with HIV (HHS [OI adult] 2022).</p></div>
<div class="block brc drugH1Div" id="F152356"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin and its active metabolite (14-hydroxyclarithromycin) are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of clarithromycin in breast milk is available from 12 breastfeeding women taking oral clarithromycin 250 mg twice daily for puerperal infections. Serial blood and milk samples were obtained at timed intervals. Both clarithromycin and its active metabolite, 14-hydroxyclarithromycin, were present in breast milk. The mean peak clarithromycin milk concentration was 0.85 mg/L ± 0.12 mg/L at 2.2 ± 0.2 hours after the dose; peak 14-hydroxyclarithromycin concentrations were 0.63 mg/L ± 0.08 mg/L at 2.8 ± 0.3 hours after the dose. The half-lives of clarithromycin and 14-hydroxyclarithromycin in breast milk were 4.3 ± 0.3 hours and 9 ± 1.2 hours, respectively (Sedlmayr 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer calculated the estimated daily infant dose of drug and active metabolite via breast milk to be 136 mcg/kg/day (relative infant dose [RID] &lt;1% based on a therapeutic infant dose of 15 mg/kg/day). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Decreased appetite, diarrhea, rash, and somnolence have been reported in breastfed infants exposed to macrolide antibiotics (Goldstein 2009). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002). In addition, an increased risk for infantile hypertrophic pyloric stenosis (IHPS) may be present in infants who are exposed to macrolides via breast milk, especially during the first two weeks of life (Lund 2014); however, data are conflicting (Goldstein 2009). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F6699915"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BUN, creatinine, LFTs, audiogram with prolonged use, ECG for QTc prolongation (ATS/ERS/ESCMID/IDSA [Daley 2020]).</p></div>
<div class="block pha drugH1Div" id="F152334"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exerts its antibacterial action by binding to 50S ribosomal subunit resulting in inhibition of protein synthesis. The 14-OH metabolite of clarithromycin is twice as active as the parent compound against certain organisms.</p></div>
<div class="block phk drugH1Div" id="F152351"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Rapid; food delays rate, but not extent of absorption</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release: Fasting is associated with ~30% lower AUC relative to administration with food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely into most body tissues; manufacturer reports no data in regards to CNS penetration</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 42% to 70% (Peters, 1992)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially hepatic via CYP3A4; converted to 14-OH clarithromycin (active metabolite); undergoes extensive first-pass metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Immediate release: Clarithromycin: 3-7 hours; 14-OH-clarithromycin: 5-9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Immediate release: 2-3 hours; Extended release: 5-8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (20% to 40% as unchanged drug; additional 10% to 15% as metabolite); feces (29% to 40% mostly as metabolites) (Ferrero 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Approximates normal GFR</p></div>
<div class="block phksp drugH1Div" id="F51220845"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The pharmacokinetics of clarithromycin were altered in subjects with impaired renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The 14-OH clarithromycin concentrations were lower in subjects with hepatic impairment but may be partially offset by an increase in renal clearance of clarithromycin.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Concentration (AUC/minimum inhibitory concentration [MIC]) and time (time/MIC) dependent (Bauernfeind 1995; Craig 2001a; Craig 2001b; Periti 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≤7 years of age: Multiple doses (steady state): 7.5 mg/kg/dose every 12 hours: 4.6 ± 2.08 mg/L (Gan 1992).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, multiple doses (steady state):</p>
<p style="text-indent:-2em;margin-left:10em;">IR tablet: 250 mg every 12 hours: 1 to 2 mg/L; 500 mg every 8 to 12 hours: 3 to 4 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">ER tablet: 500 mg once daily: 1 to 2 mg/L; 1 g once daily: 2 to 3 mg/L.</p>
<p style="text-indent:-2em;margin-left:6em;">AUC:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≤7 years of age: Multiple doses (steady state): 7.5 mg/kg/dose every 12 hours: AUC<sub>0-6</sub>: 15.7 ± 6.72 mg•hour/L (Gan 1992).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, multiple doses (steady state): IR tablet: 250 mg every 12 hours: AUC<sub>24 </sub>7.85 ± 2 mg•hour/L (Kees 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">Postantibiotic effect: Varies based on organism:</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-positive/gram-negative respiratory pathogens: 1.7 to 3.8 hours (Ferrara 1996).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycobacterium avium</i> complex: 5.5 to 18 hours (Ellis 1995; Horgen 1999).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F152358"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarex | Claridar | Clariglen | Clarimac | Claritt | Claritt xl | Clariva | Clarixin | Emimycin | Eracid | Klacid | Klaracid | Klarith | Resclar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aeroxina | Aeroxina u.d. | Centromicina | Claribiotic | Claricina | Clarimax | Clarimax u.d. | Claritrolabsa | Claritrom | Claritromicina | Claritromicina fabra | Claritromicina hlb | Claritromicina northia | Claritromicina richet | Claritromicina vannier | Clarovil | Clarovil ud | Clasid | Clatromicin fuerte | Corixa | Corixa UD | Fada claritromicin | Fadamicina | Finasept | Ira | Iset | Iset ud | Kailasa | Klaricid | Klonacid | Macromicina | Neumodryl | Orabiot ud | Quotal | Quotal ud | Soferax | Tuclarit | Windar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin 1a pharma | Clarithromycin accord | Clarithromycin actavis | Clarithromycin arcana | Clarithromycin hameln | Clarithromycin hikma | Clarithromycin pfizer | Clarithromycin Sandoz | Clarithromycin stada | Clarithromycin teva | Klacid | Klacid lactobionat | Maclar</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo Clarithromycin | Clarac | Clarihexal | CLARITHRO | Clarithromycin an | Clarithromycin pfizer | Cm clarithromycin | Genrx clarithromycin | Kalixocin | Klacid | Tw clarithromycin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Binoclar | Claricin | Clarin | Clarith | Clarox | Clix | Klabex | Klabid | Klaricid | Klarix | Maclar | Macrobid | Pneumoclar | Remac | Rolacin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Biclar | Clarithromed | Clarithromycin krka | Clarithromycin teva | Clarithromycine abbott | Clarithromycine EG | Clarithromycine Mylan | Clarithromycine sandoz | Clarithromycine teva | Heliclar | Maclar | Monaxin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Binoclar | Claricin | Claryl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin abr | Claxirit | Fromilid | Fromilid uno | Kaplon | Klabax | Klacar | Klacid | Klacid SR | Klerimed | Lekoklar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bulansi | Clabat | Clamicin | Clarilib | Clarimax | Clarineo | Claritab | Claritromicina | Claritron | Clatorin | Cozib | Helicocid | Klaricid | Klaricid ud | Klaritril | Klaroxil | Lagur | Ritromic</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarithrocin | Clarithromycin - 1A Pharma | Clarithromycin actavis | Clarithromycin labatec | Clarithromycin mepha | Clarithromycin Sandoz | Clarithromycin spirig hc | Claromycin | Klacid | Klaciped</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Acem | Claricin | Claritromicina generis | Clariva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cempax | Claribay | Clarimax | Claritromicina | Clatic | Euromicina | Extrem | Infex | Klaricid | Mus | Preclar</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A rui | An ji er ning | Ao ni ya | Bai hong you | Bei qi li | Claricin | Jia li | Ka si mai xin | Ke dun ning | Klabax | Klacid | Klacid SR | Li xin | Mo xin | Nuo bang | Sen ke | Tai bi jie | Yi chuan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bacteclar | Bactirel | Binoclar | Ciridac | Clactirel | Claribac | Claribiotic | Clarifar | Clarimisyn | Claritrol | Claritromicina | Clormicin | Fadamicina | Icncla | Klabact | Klacina | Klamicina | Klaricid | Klaricid ud | Klaridia | Klarigram | Klarigran | Klaritrol | Lagur | Maclar | Macromycin | Nutbact | Requelar | Rolicytin | Siniak | Sumiclar</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Clarem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Clarithromycin | Clarithromycin aurobindo | Clarithromycin hameln | Clarithromycin olikla | Clarithromycin teva | Fromilid | Klabax | Klacid | Lekoklar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Biaxin HP | Biclar | Clarilind | Clarithrobeta | Clarithromycin 1a pharma | Clarithromycin abz | Clarithromycin Accedo | Clarithromycin accord | Clarithromycin al | Clarithromycin Amneal | Clarithromycin Aristo | Clarithromycin basics | Clarithromycin ct | Clarithromycin dura | Clarithromycin Eberth | Clarithromycin Ethypharm | Clarithromycin HEC Pharm | Clarithromycin Heumann | Clarithromycin hexal | Clarithromycin Inresa | Clarithromycin lindopharm | Clarithromycin Martindale Pharma | Clarithromycin micro labs | Clarithromycin pfizer | Clarithromycin ratiopharm | Clarithromycin Sandoz | Clarithromycin stada | Clarithromycin TAD | Klacid | Klaricid | Mavid</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin "PCD" | Klacid uno</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Anticlar | Bactirel | Binoclar | Claribac | Claribiotic | Clarilap | Clarimicin | Claritrol | Claritromicina | Claritromicina lam | Clatrix | Fratromicin | Helozym | Infex | Infex DU | Klabax | Klaricid | Klaricid ud | Klaristat | Maclar | Macrocorp | Preclar | Ritromi</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bacterfin | Bactirel | Binoclar | Bioclarit | Clamycin | Clanil | Clarimed | Clarimox | Clariston | Claritrobac | Claritrol | Claritromicina | Claritromicina MK | Claritromicina-R | Claritromina | Clatic | Claxid | Claxtat | Eymicin | Helimox | Helozym | Infex | Italclar | Klabax | Klaricid | Klarstar | Lagur | Pre Clar | Pre Clar UD | Rasermicina | Ritromi | Tibex | Trimex | Xilin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin grindeks | Fromilid | Klabax | Klacid | Klacid SR | Klacid swc | Klatex | Klerimed | Lekoklar</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alphaclarin | Bedrevida xl | Claribiotic | Clarikan | Clarimax | Clarimycin | Clariostrong | CLARITHRO | Infectocure | Kapifectin | Klacid | Klacid xl | Klarimix | Larithrocin | Prinsocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bremon | Claritromicina | Claritromicina accord | Claritromicina Almus | Claritromicina aphar | Claritromicina aurovitas | Claritromicina bexal | Claritromicina bluepharma | Claritromicina combino | Claritromicina Cuve | Claritromicina edigen | Claritromicina grapa | Claritromicina juventus | Claritromicina kern | Claritromicina kern pharma | Claritromicina krka | Claritromicina merck | Claritromicina mundogen | Claritromicina Mylan | Claritromicina normon | Claritromicina pfizer | Claritromicina pharmacia | Claritromicina pharmagenus | Claritromicina Ranbaxy | Claritromicina sandoz | Claritromicina tarbis | Claritromicina Tecnimede | Claritromicina teva | Claritromicina Unidia TecniGen | Claritromicina ur | Claritromicina Vegal | Klacid | Kofron</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Apo Clarithromycin | Asrithro | Claranta | Clarem | Clarimin | Clarimycin | Clarithromycin hec | Claritt | Klerimed | Macrol | Uniklar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin accord | Clarithromycin hexal | Clarithromycin krka | Clarithromycin Sandoz | Cymoklar | Klacid | Klacid od | Zeclar</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin accord | Clarithromycin evolupharm | Clarithromycine abbott | Clarithromycine Almus | Clarithromycine arrow | Clarithromycine biogaran | Clarithromycine EG | Clarithromycine Evolugen | Clarithromycine HCS | Clarithromycine Mylan | Clarithromycine Qualimed | Clarithromycine Ranbaxy | Clarithromycine teva | Mononaxy | Monozeclar | Naxy | Zeclar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin | Klaricid | Klaricid IV | Klaricid Paediatric | Klaricid XL | Xetinin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Arecid | Chlamydicin | Claridus | Claripen | Clarithrocin | Clarithromycin Generics | Clarithromycin/mylan | Claromycin | Eliben | Ezumycin | Geromycin | Glartin | Klaretop | Klarexyl | Klaribros | Klaricid | Klarifar | Klarifect | Klarimac | Klarithrin | Klaroxin | Klazidem | Laromin | Lyoclar | Macladin | Maxigan | Maxilin | Odycin | Pharicid | Primocid | Riclemed | Rithroprol | Sanicet | Sythro | Thriamox | Tromypen | Viaclar | Zeclaren</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acadin | Baclecin | Clacin | Clarem | Clarie | Clarithromycin stella | Clarytas | Fascar | Jmp clarithromycin | Karicin | Klacid | Klerimed | Maxilin | Synclar | Vick-Clarcid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fromilid | Fromilid uno | Klarc | Lekoklar | Makcin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cidoclar | Clarithromycin azevedos | Clarithromycin Mylan | Fromilid | Fromilid uno | Klabax | Klacid | Klamiran | Klari | Klarigen | Klarilid | Lekoklar</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abbotic | Bicrolid | Binoklar | Clacine | Clambiotic | Clapharma | Claros | Comtro | Hecobac | Helitic | Klarid | Orixal | Twintic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clarie LA | Clarithromycin krka | Clarosip | Claryl | Clonocid | Clorom | Clorom XL | Klacid | Klacid iv | Klacid la | Klaram | Klariger | Minatev la</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Klacid | Klaridex | Klarin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acem | Aliclair | Anaclar | Aromac | Biclar | Bioclar | C cin | Celex | Clabid | Clamycin | Clar | Claraxo | Clarbact | Clarger | Claribid | Claricin | Clarie | Clarigard | Clarigen | Clarimin | Clarinova | Claripax | Claristar | Clarital | CLARITHRO | Clariwin | Clariwok | Clear | Cloff | Crixan | Cutimac | Heliclar | Hospimycin | Ibiclar | Klacid | Klacin | Klarim | Maclar | Macroclar | Megamac | Monoclar | Neklitro | Nuclear | Plugclar | Synclar | Truclar | Urclar</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Clarithrosam | Claritrom</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clamodin | Claritrol | Claritromicina | Claritromicina accord | Claritromicina Almus | Claritromicina altan | Claritromicina Doc | Claritromicina dr. reddy's | Claritromicina EG | Claritromicina hikma | Claritromicina MG | Claritromicina Pensa | Claritromicina Ranbaxy | Claritromicina sandoz | Claritromicina TAD | Claritromicina teva | Clarmac | Klacid | Kloreniss | Kruklar | Macladin | Madiclar | Soriclar | Veclam | Winclar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Claranta | Claridar | Claritop | Claritt | Claritt xl | Clarix | Clarixin | Eracid | Joclar | Klacid | Klamed | Klaribac | Klarilide | Klarimid | Klaxin | Macromax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Clarith | Clarithromycin ph | Claroycin | Klaricid | Likmoss | Minebase</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acem | Aziclar | Cipclar | Clamycin | Claranta | Claricor | Claricos | Clarie | Clarie od | Clarifred | Clarimin | Clarion | Claritek | Claritek xl | Claritron | Clariwin | Clarix | Clarized | Clarizide | Claryth | Cleron | Clith | Deklarit | Klacid | Klacid iv | Klacid p | Klacid xl | Klerimed | Neklitro | Neo klar | Niclar | Remac | Zynclar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aprogen clarithromycin | Auskle | Br clar | C-clarin | Celltrion clarithromycin | Ciracle | Clabicks | Clabio | Clabit | Clacid | Clacin | Clad | Clafacin | Claicin | Clalisin | Clamacin | Clamin | Clamisin | Clamon | Clamycin | Clana | Claniz | Clanmycin | Clao | Claone | Clar | Clara | Clari | Clari xl | Claric | Claricin | Clarid | Claridon | Clarifin | Clarimacin | Clarimicin | Clarin | Clarion | Clarione | Clariro | Clarisin | Clarith | Clarithromycin schnell | Claritin | Clarium | Clarix | Claro | Clarocin | Clarod | Claroma | Clarosin | Claroxin | Clarymasin | Clasin | Clasta | Clath | Clathro | Clathrocin | Clatomin | Claton | Clatron | Clatwo | Clavix | Claxin | Claycin | Clazin | Clcid | Clearmycin | Cliacin | Clirocin | Clithro | Clitocin | Clocid | Clocin | Clolid | Clomacin | Clomicin | Clomisin | Clomycin | Clorid | Clotin | Clycin | Craecid | Craerisin | Craycin | Crecid | Crema | Criasine | Croracin | Cyclean | Cyclin | Daewoongbio clarithromycin | Doknip claridone | Dongkwang clarithromycin | Heliclo | Helico | Heracin | Hrasin | Il sung clarithromycin | Ilsung clarithromycin | Jalicid | Jecli | Jw clarithromycin | Klaccid | Klacid | Klaricid | Klaricid xl er | Klaris | Kwangdong clarithromycin | Larith | Lathrocin | Limaclo | Mabid | Maxrocin | New clato | Piclo | Pilocin | Pylosin | Pyrocin | Reclesiin | Retos | Reyon clarithromycin | Ritcin | Rithromycin | Rpclari | Samsung clarithromycin | Sceclasin | Shuclari | Suclari | Tdcle | Xcyron | Yooyoung clarithromycin | Youngil clarithromycin | Youngpoong clarithromycin | Yuyu clarithromycin | Zecla | Zeclar</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarex | Claridar | Clarimac | Clarithromycin Sandoz | Claritt | Claritt xl | Clariva | Cleron | Emimycin | Klacid | Klaribac | Klarith | Klerimed | Resclar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarem | Claridar | Clarikan | Cleron | Crixan | Eracid | Joclar | Klacid | Klaribac | Klerimed | Macrol | Macromax | Rithrocid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Clarimin | Clarithromyc actiopharma | Clarithromycin actavis | Clarithromycin Eberth | Clarithromycin Ingen Pharma | Fromilid | Fromilid duo | Fromilid uno | Klabax | Klacid | Klatex | Klerimed | Klerimet | Lekoklar</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Biclar | Clarithromycin hexal | Clarithromycin ratiopharm | Clarithromycine abbott | Clarithromycine EG | Heliclar | Maclar | Monaxin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin actavis | Clarithromycin unifarma | Fromilid | Fromilid uno | Klabax | Klacid | Klatex | Klerimed | Lekoklar | Synclar</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">C bac | Cladia | Claril | Clazen | Eracid | Monozeclar | Zeclar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adel | Arlecyn K | Clahexal | Claritromicina | Claritromicina landsteiner | Clatrocin | Clearmicin | Collitred | Crixan | Crolisil | Declacil | Doycur | Fhisfal | Gervaken | Kausil | Klabet | Klaricid | Klaricid 12h | Klaricid hp | Klaricid od | Klarix | Klarmyn | Klarpharma | Krobicin | Mabicrol | Mabicrol sr | Macrobac | Moxitral | Pisatrom | Pivadexen | Quedox | Rolicytin | Solievo | Valucina | Vikrol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avexus | Claranta | Clarie od | Clarimycin | Clarithromycin stada | Claritrox | Clarytas | Crixan | Fromilid uno | Klacid</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Biomeclarocin | Clar | Claret | Clariblue | Claricin | Clarimax | Claritek | Clarithrmax | Clarithroxal | Clariva | Clarthrime | Deoxin ph | Hanclaro | Kch clarithromycin | Klacid paediatric | Klaritab | Makinga clarithromycin | Novalide er | Pauco clarithromycin | Pocco clarithromycin | Sivoclarithromycin | Spectra clarithromycin | Thryromyc</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Claritromycine | Claritromycine accord | Claritromycine alpharma | Claritromycine Cf | Claritromycine pch | Claritromycine Sandoz | Klacid | Klaricid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin accord | Clarithromycin Sandoz | Klacid | Klacid od</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo Clarithromycin | Clarac | Klacid</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Clariva</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bildren | Binoclar | Bioticlar | Clarbact | Claribiot | Clarikem | Clarilux | Clarimacrol | Clarimed | Clarimicina | Clariquilab | Claritress | Claritrol | Claritromac | Claritromicina | Claritrox | Claritt | Clarivit | Clariwin | Clarix | Clatromicin | Claxid | Clofar | Dicupal | Dinaxil | Infex | Karid | Kl bac | Klabax | Klaricid | Klarifor | Klariplus | Klaritpharma | Klaritpharma pediatrico | Klarixol | Lagur | Lubek | Macromicid | Marviclar | Preclar | Ressclaroll</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Accethrom | Acroxyn | Baclecin | Bruclar | Bysclas | Clabet | Clamycin | Clarbact | Claribax | Claricare | Clarie | Clarifix | Clarigen | Clariget | Clarilide | Clarimid | Claristad | Clarithrocid | Clarithromed | Clarithromyc Winthrop | Clarithromycin Sandoz | Clarithrophil | Clariva | Clariwin | Claryl | Claryn | Clistanex | Fevaxid ds | Hamun | Klaitrene | Klarcyn | Klaricid | Klarid | Klarika | Klarimac | Klaripas | Klarithix | Klarix | Klarmyn | Klaryth | Klaryz | Klaxid | Klaz | Klixin | Larizin | Maclar | Macrodin | Macronox | Maxulid | Neo klar | Onexid | Oracid | Pediaklar | Pharex clarithromycin | Rahmacin | Ritemed clarithromycin | Ritromax | Supalide | Sythromycin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Afoxin | Amiclar | Amigo | Astemycin | Bioclar | Bv clar | C lar | C throcin | Calphacin fort | Caltis | Canter | Canter ds | Carol | Chamarat | Cinfold | Clacin | Clafax | Clagacy | Clamac | Clamac xl | Clamaf | Clamont | Clamycin | Clara | Clarabac | Claract | Claract ds | Claramed | Claramet | Claraze | Claribin | Claricin | Claricure | Claricure sr | Clarient xl | Clarifaas | Clarifold | Clarilide | Clarimor | Clarimyth | Clarinac | Clariocin | Clarion | Clarip | Clariscot | Clariset | Clarish | Claritab | Clarital | Claritek | CLARITHRO | Clarithro ds | Clariton | Claritro | Claritus | Clarivant | Clariweb | Clariwin | Clariza | Clarkan | Clarlet ds | Clarocin | Clarolid | Claromet | Claromy | Clarox | Clarx | Clatz | Cliff | Clithor | Clithorad | Clithrocin | Clithrocin ds | Colt ds | Colt xl | Crolid | E clar xl | E-clar | Eclaricin | El clari | Eziklar | Fascar | Gen clare | Grotic | Gt mycim | Healcin | Heliclar | Homycin | Kalidix | Kbron | Ketek | Klabid | Klacid | Klamzon | Klaribact | Klaricid | Klaridox | Klarifine | Klarim | Klarimax | Klarinor | Klarixin | Klarixin d | Klaronil | Klarox | Klary | Klegg | Kleric | Klue | Larith | Loud | Maclara | Macral | Macrocid | Macroclar | Megaklar | Megamycin | Myclar | Mythro | Neclari | Neo klar | Newmac | Novibaxin | Noviclar | Nycin | Pathocin | Pyloclar | Pyloclar ds | Rakacid | Ranker | Respiklar | Respocure | Retik | Riomed | Rithmo | Rolite | Selclar | Silkocin | Simclar | Sn clar | Spectacin | Synklar | Texklar | Triclith | Tukol | Ultima | Ultima xl | Up clar | Venrith | Wintek | Wintek ds | Wintek xl | Xelcit | Xelcit er | Xeroxyn | Xeroyn | Xuclamin | Zeclar | Zeclorin | Zithrobid | Zithrobid xr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apiclar | Clarithromycin adamed | Clarithromycin hameln | Fromilid | Fromilid uno | Klabax | Klabax ec | Klabion | Klabion uno | Klabiotic | Klacid | Klacid uno | Klaricid | Klarmin | Lekoklar | Lekoklar forte | Taclar</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Biaxin | Biaxin xl | Biaxin xl-pac</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ciclinil | Clacina | Cladia | Claritromicina | Claritromicina actavis | Claritromicina aurobindo | Claritromicina aurovitas | Claritromicina azevedos | Claritromicina bluepharma | Claritromicina generis | Claritromicina gp | Claritromicina hikma | Claritromicina labosuan | Claritromicina pharmis | Claritromicina Ratiopharm | Claritromicina TAD | Claritromicina teva | Claritromicina Zentiva | Efibac | Klacid | Klacid od | Maclar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aclarit | Bildren | Bioartan | Biomicin | Claritromicina bag pharmaceutical | Claritromicina cellofarm | Claritromicina genfar | Claritromicina la sante | Claritromicina polimed | Claritromicina promepar | Claritromicina savant pharm | Euromicina | Fadamicina | Iset | Iset ud | Klaricid | Klaricid forte | Klaricid u.d. | Novo elimicina | Pediclari | Poligram | Preclar | Soferax | Zix | Zix d.u. | Zumba clari</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarex | Claridar | Claridar XL | Clarie OD | Clarimac | Claritek | Claritt | Claritt XL | Clariva | Clarixin | Crixan OD | Deklarit | Emimycin | Eracid | Klacid | Klacid XL | Klaribac | Klerimed | Ranker | Resclar | Spectromax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clar | Claritromicina | Claritromicina aurobindo | Claritromicina teva | Claxirit | Fromilid | Fromilid uno | Klabax | Klabax mr | Klacid | Klacid SR | Klerimed | Lekoklar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Arvicin | Binoclar | Biotericin | Clarbact | Claricin | Claricitis | Clarithromycin j | Clarithromycin obl | Clarithromycin pfizer | Clarithromycin protech | Clarithromycin retard obl | Clarithromycin teva | Clarithromycin zentiva | Clarithrosin | Claromin | Ecozitrin | Ekositrin | Fromilid | Fromilid uno | Kispar | Klabax | Klabax od | Klacid | Klacine | Klarexid | Klaromin | Klasine | Klerimed | Koater | Lekoklar | Romiclar | Seidon sanovel | Sr-claren | Vero clarithromycin | Zimbaktar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Clamycin | Clarex | Claridar | Clarimac | Claritt | Claritt xl | Clariva | Clarixin | Emimycin | Eracid | Klacid | Klare | Klaribac | Klarimid | Resclar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clarithromycin aurobindo | Clarithromycin hec | Clarithromycin HEC Pharm | Clarithromycin krka | Clarithromycin ranbaxy | Clarithromycin teva | Klacid | Klaritromycin abacus medicine | Klaritromycin ebb | Klaritromycin stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bicrolid | Clari | Clarie od | Claripen | Claritron | Clariwin | Clarytas | Crixan | K-Mycin | Klacid | Klerimed</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Clarexid | Fromilid | Lekoklar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fromilid | Fromilid uno | Klabax | Klacid | Klerimed | Lekoklar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Clacina | Claricin p | Clarith | Claron | Clatrocin | Crixan | Fascar | Klacid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Clamycine | Clarid | Clarimax | CLARITHRO | Clarithromycin winthrop | Dominar | Klaribac | Klaromin | Xylar | Zeclar | Zelid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Clabel | Claricide | Clarol | Cleanomisin | Deklarit | Inclar | Klacid | Klacid-MR | Klamaxin | Klamer | Klarolid | Klaromin | Klasol | Klax | Laricid | Macrol | Maxiclar | Megasid | Oradro | Uniklar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Carimycin | Claricin | Clarocid XL | Clarthrocin | Colirocin | K-Mycin | Klarcin | Klaricid | Klaricid XL | Klarith | Naricin | Ulicin | Uricin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aziclar | Binoclar | Clabax | Clabel | Clacilar | Clamed | Claricin | Claricit | Clarithro sandoz | Clarithrocin | Clasan | Cleron | Fromilid | Fromilid uno | Klacid | Klacid SR | Klaranta | Klerimed | Lekoclar | Meristat | Oradro | Zosin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Acem | Claranta | Clarem | Clarie | Clarie od | Clarix | Clary | Klacid | Klaro 500 | Klerimed</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Berafen | Claritro | Claritromicina | Claritromicina abbott | Claritromicina Lazar | Claritromicina normon | Cliarbas | Corixa | Klaricid | Klaritrol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Binoclar | Claranta | Clarimin | Claritic | Claritromicina | Claritron | Clarivax | Deklarit | Klabax | Klaricid | Klaricid ud | Klavax | Lagur</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amfarex | Cagenine | Clairvidi | Clamisel | Clarividi | Clarixten | Fonclar | Hasanclar | Kalecin | Laclomez | Macrolacin | Meyerclari | Opeclari | Pymeclarocil | Remeclar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Apex Clarithromycin | Austell clarithromycin | Clacee | Claricule | Clarihexal | Klacid | Klacid p | Klanbicid | Klaribin | Klarithran | Klarizon | Klaryvid | Klincid | Simayla clarithromycin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Acem | Clarbact | Clarie | Clarigen | CLARITHRO | Clariwin | Klabax | Klacid | Neuclar | Synclar</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Clacee | Claranta | Klabax | Klacid iv | Klacid p | Klacid xl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14529001">
<a name="14529001"></a>ADA Division of Legal Affairs, “A Legal Perspective on Antibiotic Prophylaxis,” <i>J Am Dent Assoc</i>, 2003, 134(9):1260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/14529001/pubmed" id="14529001" target="_blank">14529001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs, “Combating Antibiotic Resistance,” <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8851453">
<a name="8851453"></a>Amsden GW, “Erythromycin, Clarithromycin, and Azithromycin: Are the Differences Real?” <i>Clin Ther</i>, 1996, 18(1):56-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8851453/pubmed" id="8851453" target="_blank">8851453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group [published correction appears in <i>MMWR Recomm Rep</i>. 2013;62(35):730]. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8021763">
<a name="8021763"></a>Aspin MM, Hoberman A, McCarty J, et al, “Comparative Study of the Safety and Efficacy of Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Acute Otitis Media in Children,” <i>J Pediatr</i>, 1994, 125(1):136-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8021763/pubmed" id="8021763" target="_blank">8021763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8557398">
<a name="8557398"></a>Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. <i>Infection</i>. 1995;23(5):316-321. doi:10.1007/BF01716300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8557398/pubmed" id="8557398" target="_blank">8557398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biaxin.1">
<a name="Biaxin.1"></a>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biaxin.2">
<a name="Biaxin.2"></a>Biaxin (clarithromycin) [product monograph]. Etobieoke, Ontario, Canada: BGP Pharma ULC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9809971">
<a name="9809971"></a>Bonow RO, Carabello B, de Leon Jr, AC, et al, “ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease),” <i>J Am Coll Cardiol</i>, 1998, 32(5):1486-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9809971/pubmed" id="9809971" target="_blank">9809971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701406">
<a name="21701406"></a>Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(6):646-650. doi:10.1097/MPG.0b013e318229c769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21701406/pubmed" id="21701406" target="_blank">21701406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i> 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28653787">
<a name="28653787"></a>Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. <i>Helicobacter</i>. 2017;22(5):e12400. doi:10.1111/hel.12400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28653787/pubmed" id="28653787" target="_blank">28653787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30899912">
<a name="30899912"></a>Callahan SJ, Vranic A, Flors L, Hanley M, Stoler MH, Mehrad B. Sporadic obliterative bronchiolitis: case series and systematic review of the literature. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2019;3(1):86-93. doi:10.1016/j.mayocpiqo.2018.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/30899912/pubmed" id="30899912" target="_blank">30899912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong B, “American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,” <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112. doi:10.1093/cid/cir1043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1474166">
<a name="1474166"></a>Chu SY, Wilson DS, Guay DR, et al, “Clarithromycin Pharmacokinetics in Healthy Young and Elderly Volunteers,” <i>J Clin Pharmacol</i>, 1992, 32(11):1045-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1474166/pubmed" id="1474166" target="_blank">1474166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mayne.2">
<a name="Mayne.2"></a>Clarithromycin extended-release tablets [prescribing information]. Greenville, NC: Mayne Pharma; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.1">
<a name="Actavis.1"></a>Clarithromycin extended-release tablets [prescribing information]. Parsippany, NJ: Actavis Pharma; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Clarithromycin suspension [prescribing information]. Princeton, NJ: Sandoz; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ajanta.1">
<a name="Ajanta.1"></a>Clarithromycin tablets [prescribing information]. Bridgewater, NJ: Ajanta Pharma USA Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cornia.1">
<a name="Cornia.1"></a>Cornia P, Lipsky BA. Pertussis infection in adolescents and adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11524724">
<a name="11524724"></a>Craig WA. Does the dose matter? <i>Clin Infect Dis.</i> 2001b;33(suppl 3):S233-S237. doi:10.1086/321854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/11524724/pubmed" id="11524724" target="_blank">11524724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11419669">
<a name="11419669"></a>Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. <i>Respir Med.</i> 2001a;95(suppl A):S12-S19; discussion S26-S27. doi:10.1016/s0954-6111(01)90023-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/11419669/pubmed" id="11419669" target="_blank">11419669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowe.1">
<a name="Crowe.1"></a>Crowe SE. Treatment regimens for Helicobacter pylori. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.<i> Clin Infect Dis.</i> 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9178793">
<a name="9178793"></a>Dajani AS, Taubert KA, Wilson W, et al, “Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,” <i>JAMA</i> 1997, 277(22):1794-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9178793/pubmed" id="9178793" target="_blank">9178793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1684980">
<a name="1684980"></a>Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. <i>J Hosp Infect</i>. 1991;19(suppl A):S29-S37. doi:10.1016/0195-6701(91)90215-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1684980/pubmed" id="1684980" target="_blank">1684980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8593025">
<a name="8593025"></a>Ellis LC, Benson CA, Koenig GI, Trenholme GM. Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. <i>Antimicrob Agents Chemother.</i> 1995;39(12):2803-2806. doi:10.1128/AAC.39.12.2803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8593025/pubmed" id="8593025" target="_blank">8593025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team:Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467303">
<a name="18467303"></a>Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. <i>J Antimicrob Chemother</i>. 2008;62(3):442-450. doi: 10.1093/jac/dkn201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/18467303/pubmed" id="18467303" target="_blank">18467303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18611754">
<a name="18611754"></a>Ferrara A, Dos Santos C, Cimbro M, Grassi GG. Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens. <i>Int J Antimicrob Agents.</i> 1996;7(3):181-186. doi:10.1016/s0924-8579(96)00320-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/18611754/pubmed" id="18611754" target="_blank">18611754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1976065">
<a name="1976065"></a>Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and Disposition of Clarithromycin in Man. <i>Drug Metab Dispos</i>. 1990;18(4):441-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1976065/pubmed" id="1976065" target="_blank">1976065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM Jr. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-i22. doi: 10.1136/thoraxjnl-2015-207360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8222460">
<a name="8222460"></a>Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. <i>Clin Pharmacokinet</i>. 1993;25(3):189-204. doi:10.2165/00003088-199325030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8222460/pubmed" id="8222460" target="_blank">8222460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1489191">
<a name="1489191"></a>Gan VN, Chu SY, Kusmiesz HT, Craft JC. Pharmacokinetics of a clarithromycin suspension in infants and children. <i>Antimicrob Agents Chemother.</i> 1992;36(11):2478-2480. doi:10.1128/AAC.36.11.2478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1489191/pubmed" id="1489191" target="_blank">1489191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al, "Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute <i>Streptococcal pharyngitis</i>: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics," <i>Circulation</i>, 2009, 119(11):1541-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11709360">
<a name="11709360"></a>Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y. Newer macrolides as empiric treatment for acute Q fever infection. <i>Antimicrob Agents Chemother</i>. 2001;45(12):3644-3646. doi: 10.1128/AAC.45.12.3644-3646.2001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/11709360/pubmed" id="11709360" target="_blank">11709360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8403355">
<a name="8403355"></a>Goldman MP and Longworth DL, “The Role of Azithromycin and Clarithromycin in Clinical Practice,” <i>Cleve Clin J Med</i>, 1993, 60(5):359-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8403355/pubmed" id="8403355" target="_blank">8403355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19366316">
<a name="19366316"></a>Goldstein LH, Berlin M, Tsur L, et al, "The Safety of Macrolides During Lactation," <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19366316/pubmed" id="19366316" target="_blank">19366316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Griffith.1">
<a name="Griffith.1"></a>Griffith DE. Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guay.1">
<a name="Guay.1"></a>Guay DR, “Pharmacokinetics of New Macrolides,” <i>Infect Med</i>, 1992, 9(Suppl A):9-13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8295810">
<a name="8295810"></a>Guay DR and Craft JC, “Overview of the Pharmacology of Clarithromycin Suspension in Children and a Comparison With That in Adults,” <i>Pediatr Infect Dis J</i>, 1993, 12(12 Suppl 3):106-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8295810/pubmed" id="8295810" target="_blank">8295810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1530914">
<a name="1530914"></a>Hardy DJ, Guay DR, Jones RN. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. <i>Diagn Microbiol Infect Dis</i>. 1992;15(1):39-53. doi:10.1016/0732-8893(92)90055-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1530914/pubmed" id="1530914" target="_blank">1530914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002709">
<a name="28002709"></a>Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. <i>N Engl J Med</i>. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28002709/pubmed" id="28002709" target="_blank">28002709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10030545">
<a name="10030545"></a>Horgen L, Legrand E, Rastogi N. Postantibiotic effects of rifampin, amikacin, clarithromycin and ethambutol used alone or in various two-, three- and four-drug combinations against Mycobacterium avium. <i>FEMS Immunol Med Microbiol.</i> 1999;23(1):37-44. doi:10.1111/j.1574-695X.1999.tb01714.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/10030545/pubmed" id="10030545" target="_blank">10030545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117692">
<a name="24117692"></a>Huang J, Zhou L, Geng L, et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1230-1235. doi:10.1111/apt.12516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/24117692/pubmed" id="24117692" target="_blank">24117692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11529259">
<a name="11529259"></a>Hunter MH, King DE. COPD: management of acute exacerbations and chronic stable disease. <i>Am Fam Physician</i>. 2001;64(4):603-612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/11529259/pubmed" id="11529259" target="_blank">11529259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8176574">
<a name="8176574"></a>Husson RN, Ross LA, Sandelli S, et al, “Orally Administered Clarithromycin for the Treatment of Systemic <i>Mycobacterium avium</i> Complex Infection in Children With Acquired Immunodeficiency Syndrome,” <i>J Pediatr</i>, 1994, 124(5 Pt 1):807-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8176574/pubmed" id="8176574" target="_blank">8176574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16339220">
<a name="16339220"></a>Jespersen CM, Als-Nielsen B, Damgaard M, et al, “Randomised Placebo Controlled Multicentre Trial to Assess Short Term Clarithromycin for Patients with Stable Coronary Heart Disease: CLARICOR Trial,” <i>BMJ</i>, 2006, 332(7532):22-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16339220/pubmed" id="16339220" target="_blank">16339220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541262">
<a name="28541262"></a>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). <i>J Pediatr Gastroenterol Nutr</i>. 2017;64(6):991-1003. doi:10.1097/MPG.0000000000001594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28541262/pubmed" id="28541262" target="_blank">28541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12854636">
<a name="12854636"></a>Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. <i>Respir Med</i>. 2003;97(7):844-850. doi: 10.1016/s0954-6111(03)00042-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/12854636/pubmed" id="12854636" target="_blank">12854636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7499006">
<a name="7499006"></a>Kees F, Wellenhofer M, Grobecker H. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. <i>Infection</i>. 1995;23(3):168-172. doi:10.1007/BF01793859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7499006/pubmed" id="7499006" target="_blank">7499006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.2020">
<a name="King.2020"></a>King TE. Overview of bronchiolar disorders in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21558964">
<a name="21558964"></a>Koletzko S, Jones NL, Goodman KJ, et al. Evidence-Based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21558964/pubmed" id="21558964" target="_blank">21558964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824827">
<a name="20824827"></a>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. <i>Cochrane Database Syst Rev</i>. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/20824827/pubmed" id="20824827" target="_blank">20824827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25171023">
<a name="25171023"></a>Kutluk G, Tutar E, Bayrak A, et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?. <i>Eur J Gastroenterol Hepatol</i>. 2014;26(11):1202-1208. doi:10.1097/MEG.0000000000000190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/25171023/pubmed" id="25171023" target="_blank">25171023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21911976">
<a name="21911976"></a>Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. <i>BMJ</i>. 2014;348:1908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21911976/pubmed" id="21911976" target="_blank">21911976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876601">
<a name="31876601"></a>Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. <i>Pediatr Infect Dis J</i>. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/31876601/pubmed" id="31876601" target="_blank">31876601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10212011">
<a name="10212011"></a>McConnell SA and Amsden GW, “Review and Comparison of Advanced-Generation Macrolides Clarithromycin and Dirithromycin,” <i>Pharmacotherapy</i>, 1999, 19(4):404-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/10212011/pubmed" id="10212011" target="_blank">10212011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30978536">
<a name="30978536"></a>McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. <i>Clin Gastroenterol Hepatol</i>. 2020;18(1):89-98. doi: 10.1016/j.cgh.2019.03.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/30978536/pubmed" id="30978536" target="_blank">30978536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22760494">
<a name="22760494"></a>Nizič T, Velikanje E, Ružić-Sabljić E, Arnež M. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. <i>Wien Klin Wochenschr</i>. 2012;124(13-14):427-433. doi:10.1007/s00508-012-0194-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/22760494/pubmed" id="22760494" target="_blank">22760494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10078776">
<a name="10078776"></a>Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. <i>J Chemother.</i> 1999;11(1):11-27. doi:10.1179/joc.1999.11.1.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/10078776/pubmed" id="10078776" target="_blank">10078776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379907">
<a name="1379907"></a>Peters DH and Clissold SP, “Clarithromycin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties, and Therapeutic Potential,” <i>Drugs</i>, 1992, 44(1):117-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1379907/pubmed" id="1379907" target="_blank">1379907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>“Pimozide (Orap) Contraindicated With Clarithromycin (Biaxin) and Other Macrolide Antibiotics,” <i>FDA Medical Bulletin</i>, October 1996, 3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30043070">
<a name="30043070"></a>Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel. <i>JAMA</i>. 2018;320(4):379-396. doi: 10.1001/jama.2018.8431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/30043070/pubmed" id="30043070" target="_blank">30043070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879279">
<a name="23879279"></a>Sedlak T, Shufelt C, Iribarren C, et al, "Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval," <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23879279/pubmed" id="23879279" target="_blank">23879279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8370491">
<a name="8370491"></a>Sedlmayr T, Peters F, Raasch W, Kees F. Clarithromycin, a new macrolide antibiotic. Effectiveness in puerperal infections and pharmacokinetics in breast milk. <i>Geburtshilfe Frauenheilkd</i>. 1993;53(7):488-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8370491/pubmed" id="8370491" target="_blank">8370491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.1">
<a name="Sethi.1"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.1">
<a name="Spach.1"></a>Spach DH. Bartonella infections in people with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2020">
<a name="Spach.2020"></a>Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7827672">
<a name="7827672"></a>Stafstrom CE, Nohria V, Loganbill H, et al, “Erythromycin-induced Carbamazepine Toxicity: A Continuing Problem,” <i>Arch Pediatr Adolesc Med</i>, 1995, 149(1):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7827672/pubmed" id="7827672" target="_blank">7827672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19330931">
<a name="19330931"></a>Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. <i>J Pediatr Gastroenterol Nutr</i>. 2009;48(4):431-436. doi:10.1097/mpg.0b013e318182e716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19330931/pubmed" id="19330931" target="_blank">19330931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16181387">
<a name="16181387"></a>Talley NJ and Vakil N, “Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,” <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16181387/pubmed" id="16181387" target="_blank">16181387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16340941">
<a name="16340941"></a>Tiwari T, Murphy TV, Moran J; National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. <i>MMWR Recomm Rep.</i> 2005;54(RR-14):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16340941/pubmed" id="16340941" target="_blank">16340941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated August 18, 2021. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated February 17, 2022. Accessed January 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8477575">
<a name="8477575"></a>Wallace RJ Jr, Brown BA, and Griffith DE, “Drug Intolerance to High-Dose Clarithromycin Among Elderly Patients,” <i>Diagn Microbiol Infect Dis</i>, 1993, 16(3):215-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8477575/pubmed" id="8477575" target="_blank">8477575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al, "Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update," <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in <i>Circulation</i>. 2007;116(15):e376-e377]. <i>Circulation.</i> 2007;116(15)1736-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12634663">
<a name="12634663"></a>Witt A, Sommer EM, Cichna M, et al, "Placental Passage of Clarithromycin Surpasses Other Macrolide Antibiotics," <i>Am J Obstet Gynecol</i>, 2003, 188(3):816-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/12634663/pubmed" id="12634663" target="_blank">12634663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23215911">
<a name="23215911"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23215911/pubmed" id="23215911" target="_blank">23215911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>, 2007;45(7):941]. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12004720">
<a name="12004720"></a>Wynn RL, Bergman SA, Meiller TF, et al, “Antibiotics in Treating Oral-Facial Infections of Odontogenic Origin: An Update,” <i>Gen Dent</i>, 2001, 49(3):238-40, 242, 244 passim.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/12004720/pubmed" id="12004720" target="_blank">12004720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9273 Version 601.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
